团体讨论

Join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic.

6月3日(三)

5:05 - 5:45 PM

5:05 Find Your Table, Meet Your Moderator

5:10 Roundtable Breakout Discussions


Accelerating Target Discovery

TABLE: Leveraging Advanced Genomics Tools for Target Identification

Moderators: Neville Sanjana, PhD, Assistant Professor, Departments of Neuroscience and Physiology, New York University; Faculty, New York Genome Center Richie Kohman, PhD, Senior Research Scientist and Lead, Synthetic Biology Platform, Wyss Institute for Biologically Inspired Engineering, Harvard University

TABLE: Impact of Chemical Biology and Phenotypic Screening on Drug Discovery

Moderators: Jaimeen Majmudar, PhD, Principal Scientist, Chemical Biology, Pfizer Inc.

Sujatha Gopalakrishnan, PhD, Head, Molecular Screening and Characterization, AbbVie

 

  • Combining CRISPR screens and single cell analysis
  • Omics techniques for in situ analysis
  • Practical advice and things to know

Expanding Chemical & Druggable Space

TABLE: Advances and Challenges in Macrocyclic Peptide Therapeutic Development

Moderator: Vincent Guerlavais, PhD, New Modalities, Drug Discovery Consultant

  • Lead drug optimization challenges unique to stapled peptides and other macrocyclics
  • Progress using peptide-based carrier approach in the field of targeted drug delivery
  • New opportunities for peptidomimetics in the field of PROTACs and targeted protein degradation

TABLE: Comparing Biophysical Methods: When to Use What

Moderator: Scott Cowen, PhD, Independent Medicinal Chemistry Consultant

  • SPR, NMR, ITC, TSA, DEL, MST, MS-based methods, etc.
  • Integrating hits from various screening approaches

TABLE: Designing and Optimizing Small Molecule Protein Degraders

Moderators: Joe Patel, PhD, Director, Biochemistry, Biophysics & Crystallography, C4 Therapeutics, Inc. Guangrong Zheng, PhD, Associate Professor, Department of Medicinal Chemistry, College of Pharmacy, University of Florida

  • Designing small molecule degraders for tissue selectivity
  • Using biophysical and computational tools to help medicinal chemistry
  • Current challenges and knowledge gaps in protein degrader design and optimization

New Small Molecule Drug Targets

TABLE: Targeting Cellular Metabolism: Not Just for Treating Cancer Anymore

Moderator: Masha Poyurovsky, PhD, Vice President, Discovery Biology, Kadmon Corporation, LLC

  • Metabolic pathways of immune cell function -- under normal and pathologic conditions
  • Lessons from cancer biology: metabolic reprogramming of immune and cancer cells associated with transformation
  • Can targeting metabolic pathways regulate autoimmunity or inflammation?

TABLE: Gut Microbiota as a Small Molecule Drug Target

Moderator to be Announced

  • Defining bioavailability
  • Target engagement
  • Considerations for patient selection

TABLE: What Happens When You Get Off-Target Effects When You Target RNA?

Moderator to be Announced

  • How are off-target events for RNA-targeting drugs being avoided and assessed?
  • What approaches are being taken to broaden delivery, the major hurdle for RNA-targeting therapeutics?
  • After delivery what is the next challenge for RNA-targeting drugs?

Emerging Indications and Modalities

TABLE: Translational Strategies in CNS Drug Development

Moderator: Dario Doller, PhD, Director, Medicinal Chemistry, Sunovion Pharmaceuticals

  • Human as a model for human – What is the future of experimental medicine in CNS drug discovery?
  • Correlation or causation? Importance of genetic links for different CNS diseases
  • What are the attributes that have real impact minimizing risk during novel target selection?

TABLE: AI and Machine Learning in CNS Drug Development

Moderator: Istvan Enyedy, PhD, Principal Scientist, Medicinal Chemistry, Biogen

  • AI concepts and integrating into a drug discovery strategy
  • Role of AI in CNS drug discovery
  • Challenges, dangers and opportunities using AI in drug discovery

TABLE: Cellular Models for Fibrosis

Moderator: Vanessa Morales-Tirado, PhD, Principal Research Scientist, Translational Immunology, Immunology Discovery, AbbVieBioresearch Center

  • 3D multicellular models
  • Organotypic and tissue explants
  • In vitro co-culture systems

Immuno-Oncology Advances

TABLE: Tumor Immune Microenvironment

Moderator: Elizabeth Thompson, MD, PhD, Assistant Professor, Pathology and Oncology, The Johns Hopkins Hospital

  • Immune responses in early stages of tumor development
  • Profiling the tumor microenvironment
  • Predicting recurrence/progression to malignancies

TABLE: Theranostics in Immuno-Oncology

Moderator: Michael Roehrl, MD, PhD, Director, Precision Pathology Center, Memorial Sloan Kettering Cancer Center; Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medicine

  • Understanding deep proteomic approaches
  • Identifying novel biomarkers to risk-stratify patients
  • Distinguishing which tumors may be susceptible to immunological attack

Disease Modeling

TABLE: Organoids – Is It a Fad or an Enduring Technology?

Moderator: Angela Zhang, PhD, Product Manager, Epithelial Cell Biology, Research & Development, Stemcell Technologies

  • All models have advantages and disadvantages – will the pros of organoids make them worth it?
  • How have we as a field moved forward? Where are organoids best used?
  • What do we still need?

TABLE: Transitioning from Academia to Industry

Moderator: Joanna Lee, PhD, Scientist, Genentech

  • What is an industry job (i.e. day-to-day responsibilities)
  • Conducting an industry job search
  • Negotiating a compensation package

Preclinical Strategies, Models & Tools in Oncology

TABLE: Preclinical Strategies for T Cell Therapy

Moderator: Lindsay King, PhD, Associate Research Fellow, Biomedicines Design, Pfizer

  • Preclinical challenges in CAR T Cell therapy development in solid tumors
  • Exploratory assays for T Cell therapy development
  • Major translational challenges
  • Therapy breakthroughs

TABLE: Targeting Inflammasome in Cancer & Beyond

Moderator: Pushpa Jayaraman, PhD, Senior Investigator I, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research

  • Acute and chronic inflammation in oncogenesis
  • Researching inflammatory microenvironment
  • Targeting inflammasome

Advances in Drug Metabolism & Safety Testing

TABLE: Impact of Artificial Intelligence and Machine Learning on Drug Safety Assessments

Moderators: Barun Bhhatarai, PhD, Investigator, Novartis Institute for Biomedical Research Joshua Swamidass, MD, PhD, Assistant Professor, Immunology and Pathology, Laboratory and Genomic Medicine; Faculty Lead, Translational Informatics, Institute for Informatics, Washington University

  • Case studies on effective use of AI/ML for ADME/Tox assessments
  • Key questions to ask when evaluating and integrating AI/ML into existing workflows
  • Caveats on how to analyze and use the knowledge from AI/ML studies

TABLE: Traditional and Advanced Models and Strategies for Early Risk Assessments

Moderators: Terry Van Vleet, PhD, DABT, Director, Investigative Toxicology, Department of Preclinical Safety, AbbVie Paul Michalski, PhD, Investigator, Systems Modeling and Translational Biology, GlaxoSmithKline

  • Comparison of traditional 2D systems with complex 3D and microphysiological systems
  • Practical advice on use of in silico tools like DILIsym for safety predictions
  • Evaluating and integrating new tools into current safety assessments and workflow

Immuno-Oncology Biomarkers

TABLE: Tumor Immune Microenvironment

Moderator: Elizabeth Thompson, MD, PhD, Assistant Professor, Pathology and Oncology, The Johns Hopkins Hospital

  • Immune responses in early stages of tumor development
  • Profiling the tumor microenvironment
  • Predicting recurrence/progression to malignancies

TABLE: Theranostics in Immuno-Oncology

Moderator: Michael Roehrl, MD, PhD, Director, Precision Pathology Center, Memorial Sloan Kettering Cancer Center; Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medicine

  • Understanding deep proteomic approaches
  • Identifying novel biomarkers to risk-stratify patients
  • Distinguishing which tumors may be susceptible to immunological attack

Clinical and Translational Biomarkers

TABLE: Genomics and Biomarker Data Analysis

Moderator: Viswanath Devanarayan, PhD, Global Health of Statistics & Data Sciences, Charles River Laboratories

TABLE: Big Data to Select Patient Populations

Moderator: Dirk Brockstedt, PhD, CSO, RAPT Therapeutics


AI for Drug Discovery and Development

TABLE: Decoding AI: Making the Case for Artificial Intelligence in the Pharma Industry

Moderator: Amol Jadhav, PhD, Industry Consultant, Transformational Health, Frost & Sullivan

  • Adjusting pharmaceutical business models to incorporate AI technologies
  • What measures should be taken to invest and apply AI at various stages of drug development? What should be the expectation on returns?
  • Business-Academia partnerships: Pharma is looking for collaborations, shared experience from startups, academia on opportunities and expectations
  • Establishing evaluation standards and benchmarks: Can we benchmark products and technology?

TABLE: Machine Learning in Action: Moving Beyond Hype

Moderator: Sean Ekins, PhD, DSc, CEO, Collaborations Pharmaceuticals, Inc.

  • How can we go beyond the hype?
  • Putting algorithms into practice
  • How do we get to drugs faster?

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English




6月2日~4日

加速标靶发现

扩大化合物与Druggable空间

新小分子标靶

新适应症与模态

癌症免疫疗法进步

疾病模型

肿瘤治疗领域临床前研究策略的模式与工具

药物代谢与安全性测试的进步

癌症免疫疗法生物标记

临床与转译生物标记

新药发现与开发的AI

6月3日~4日

新药发现的技术


免费电子邮件通知服务